| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10919848 | Radiotherapy and Oncology | 2011 | 4 Pages |
Abstract
Based on the lack of response, the substantial toxicity of mainly gastro-intestinal origin and the reported mediocre overall and progression free survival, we cannot advise our short intensive chemoradiotherapy schedule combined with celecoxib as the standard treatment.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Marjolein J.M. Morak, Dick J. Richel, Casper H.J. van Eijck, Joost J.M.E. Nuyttens, Ate van der Gaast, Walter L. Vervenne, Esther E. Padmos, Eva E. Schaake, Olivier R.C. Busch, Geertjan van Tienhoven,